GT BIOPHARMA, INC. Other Noncash Income (Expense)
GT BIOPHARMA, INC. (GTBP) reported Other Noncash Income (Expense) of -$3.97 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2020-11-13
- GT BIOPHARMA, INC. other noncash income (expense) for the quarter ending 2020-09-30 was -$15.00K.
- GT BIOPHARMA, INC. other noncash income (expense) for the quarter ending 2019-09-30 was $0.00.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month |
|---|---|---|---|
| 2020-09-30 | -$15.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | -$3.97M 10-Q · filed 2020-11-13 | |
| 2020-06-30 | -$3.96M 10-Q/A · filed 2020-08-18 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | -$1.14M 10-Q · filed 2020-11-13 | |
| 2019-06-30 | -$1.14M 10-Q/A · filed 2020-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |